Another potential Coronavirus vaccine in tablet form goes on trial in July
London, May 16, 2020 (AltAfrica)-A new CORONAVIRUS vaccine taken in tablet form rather than an injection could be ready next year, a top scientist has said
.US biotech company Vaxart which specialises in the developing oral recombinant vaccines, have developed a coronavirus tablet for the deadly disease
Immunologist Dr. Sean Tucker is getting ready to start human trials of a vaccine in July which will be delivered in tablet form rather than through an injection.
Dr Sean Tucker, chief scientific officer at Vaxart, believes “millions of doses” of the vaccine will be ready by the start of next year.
It comes as thousands of scientists across the world are racing to find a vaccine to halt the pandemic.
Dr Tucker told the MailOnline: “My hope is that us and others will be able to have very large vats of [vaccine] material, millions and millions of doses by the end of the year, early next year.
“We hope that a vaccine solution will allow things to open up and for people to be going out and about again.”
My hope is that we will be able to have millions and millions of doses by the end of the year, early next year Dr Sean Tucker said
They currently have several contenders, all of which are being fast-tracked through trials.
The vaccines are made from a dead adenovirus – one of the causes of common colds – into which some of the 30 genes that make up Covid-19’s DNA have been inserted.
Adenoviruses are extremely common and are the cause of about ten per cent of childhood illnesses and almost every child has had at least one illness caused by adenoviruses by the time they reach ten.
Unlike most vaccines, which are made to be injected, the Vaxart drug will be delivered in tablet form.
The scientists claim this is more quickly manufactured and gets around the current global shortage of vials and syringes caused by the pandemic
In particular, Dr Tucker believes their potential coronavirus vaccine will prove effective given it is delivered into the intestine – a wet surface – which creates a “great immune response” throughout the blood.
He added: “That’s the way our vaccine works – it’s designed to mount an immune response on wet surfaces such as the respiratory tract, which Covid-19 infects.”
The vaccines are currently being tested in the lab and trialled on mice, which Dr Tucker says has shown promising results.
Earlier this month, Vaxart revealed the animal trials had shown an unusually early Immunoglobin G (IgG) response to coronavirus.
IgG are the antibodies that kill off the virus and have the potential to provide long-term protection from the bug.
People who have already had Covid-19 already have coronavirus-killing IgG antibodies and it is those that appear in antibody tests for the virus.
For Dr Tucker, the rapid production of IgG antibodies at an early stage is a promising sign that not only does his candidate vaccine work, it works fast.
Phase one human trials will begin in July using a small group of patients – which will examine whether the vaccines work and whether they produce any side effects.